NGM Biopharmaceuticals, Inc. (NGM) Tops Q3 EPS by 7c

NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) reported Q3 EPS of ($0.35), $0.07 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $580 thousand versus the consensus estimate of $2.46 million.

For earnings history and earnings-related data on NGM Biopharmaceuticals, Inc. (NGM) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Jaguar Health (JAGX) Tops Q2 EPS by 3647c
• Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance